kate Smith
March 3rd, 2009, 07:09 AM
From the March, 2009, 121doc is going to add a new medicine in its portfolio. The new product is CRESTOR. You can read brief introduction of this product below.
Crestor is a member of the drug class,statins that are used to treat high cholesterol and related conditions, and to prevent cardiovascular disease.
Japanese pharmaceutical company Shionogi has developed this product and the German pharmaceutical company AstraZeneca markets it as Crestor.
Crestor is available in tablet form (5mg, 10mg, 20mg, and 40 mg) and is taken orally. These tablets are pink, round or oval (40 mg), biconvex, film-coated, and imprinted with "ZD4522" and tablet strength. Japanese approval is in the dose range of 2.5 mg to 20 mg; therefore, smaller dose tablet forms might also be available outside of the United States. Note that 97% of worldwide sales have been at or below the 20 mg dose.
Crestor is approved for the treatment of high LDL cholesterol (dyslipidemia), total cholesterol (hypercholesterolemia) and/or triglycerides (hypertriglyceridemia).
As of 2004, rosuvastatin had been approved in 154 countries and launched in 56. The FDA has approved it in the United States on August 12, 2003.
In 2008, research showed that Crestor could reduce the risk of heart attack, stroke, and other vascular complications in patients with elevated C-reactive protein but no other risk factors.
The results of the JUPITER trial suggested that Crestor may decrease the relative risk of heart attack and stroke in patients without hyperlipidemia.
The main competitors of this drugs are lipitor and zacor.
Sales Potential:
First launched in 2003, sales of Crestor were $129 million and $908 million in 2003 and 2004, respectively, with a total patient treatment population of >4 million by the end of 2004.
Crestor sales were $2,796mn in Year 2007 and the growth as compared to 2006, was higher by $673mn. The sales of Crestor exceeded $2bn for the first time in 2006, ever since its launch in 2003.
More than 70million prescriptions were written in 2007.
Crestor sales in the US were up 57% to $1,148 million for the year. New prescriptions for statins in the US were up 18%; Crestor new prescriptions were up by 58%. Crestor new prescription market share in December 2006 was 9.6%. In other markets, Crestor sales increased by 61% on good growth in Europe (up 56%) and in Asia Pacific following launch in Australia and Japan in the second half of 2006.
So, be ready to tap this huge potential.
We are with you with the new and improved sales tracking software. The user interface and website is being updated to make it more attractive and user friendly and our affiliate team is working parallel to provide you the necessary support at every stage to enhance your marketing efforts.
For more information about Crestor, you can visit www.crestor.com.
Crestor is a member of the drug class,statins that are used to treat high cholesterol and related conditions, and to prevent cardiovascular disease.
Japanese pharmaceutical company Shionogi has developed this product and the German pharmaceutical company AstraZeneca markets it as Crestor.
Crestor is available in tablet form (5mg, 10mg, 20mg, and 40 mg) and is taken orally. These tablets are pink, round or oval (40 mg), biconvex, film-coated, and imprinted with "ZD4522" and tablet strength. Japanese approval is in the dose range of 2.5 mg to 20 mg; therefore, smaller dose tablet forms might also be available outside of the United States. Note that 97% of worldwide sales have been at or below the 20 mg dose.
Crestor is approved for the treatment of high LDL cholesterol (dyslipidemia), total cholesterol (hypercholesterolemia) and/or triglycerides (hypertriglyceridemia).
As of 2004, rosuvastatin had been approved in 154 countries and launched in 56. The FDA has approved it in the United States on August 12, 2003.
In 2008, research showed that Crestor could reduce the risk of heart attack, stroke, and other vascular complications in patients with elevated C-reactive protein but no other risk factors.
The results of the JUPITER trial suggested that Crestor may decrease the relative risk of heart attack and stroke in patients without hyperlipidemia.
The main competitors of this drugs are lipitor and zacor.
Sales Potential:
First launched in 2003, sales of Crestor were $129 million and $908 million in 2003 and 2004, respectively, with a total patient treatment population of >4 million by the end of 2004.
Crestor sales were $2,796mn in Year 2007 and the growth as compared to 2006, was higher by $673mn. The sales of Crestor exceeded $2bn for the first time in 2006, ever since its launch in 2003.
More than 70million prescriptions were written in 2007.
Crestor sales in the US were up 57% to $1,148 million for the year. New prescriptions for statins in the US were up 18%; Crestor new prescriptions were up by 58%. Crestor new prescription market share in December 2006 was 9.6%. In other markets, Crestor sales increased by 61% on good growth in Europe (up 56%) and in Asia Pacific following launch in Australia and Japan in the second half of 2006.
So, be ready to tap this huge potential.
We are with you with the new and improved sales tracking software. The user interface and website is being updated to make it more attractive and user friendly and our affiliate team is working parallel to provide you the necessary support at every stage to enhance your marketing efforts.
For more information about Crestor, you can visit www.crestor.com.